November 16, 1919 – 21:38
Montreal, April 30 / PRNewswire / –
– The Montreal Heart Institute (MHI) today announced the results of its COLchicine Cardiovascular Outcomes Trial (COLCOT) study. This central study compared the effect of colchicine on the prevention of ischemic cardiovascular disease in patients with recent myocardial infarction (MI) under standard treatment. In this study, patients receiving colchicine 0.5 mg daily, in addition to standard treatment, had a lower rate of first and recurrent ischemic cardiovascular disease compared to patients receiving standard treatment alone. These data were simultaneously in the New England Journal of Medicine (NEJM) and presented today at a scientific session of the American Heart Association (AHA).
Pharmascience Inc. is proud to have contributed to this groundbreaking clinical trial, the results of which can have a significant positive impact on patients' cardiovascular outcomes and overall public health. Inflammation in cardiovascular disease has been shown to play an important role and the results of COLCOT represent a very significant advance in linking the reduction of inflammation following a myocardial infarction with better cardiovascular outcomes.
An important aspect of the COLCOT study is that it allows a new use of colchicine, a drug used for decades to treat gout and familial Mediterranean fever. The new use of older and more established drugs involves the discovery of additional uses for drugs that have already been approved.
"Pharmascience has chosen to support healthcare innovation such as COLCOT here in Canada with the goal of promoting therapeutic innovation and improving patient outcomes with a new indication for an old, proven drug that can be delivered in a timely manner. affordable, "said Dr. David Goodman, CEO of Pharmascience. "We believe these projects fit perfectly with our desire to contribute to therapeutic advancement through responsible entrepreneurship."
The clinical use of colchicine is supported by the fact that the safety profile is well known and very affordable compared to some newer cardiovascular drugs for similar indications. New-use generics are attractive and cost-effective options for public and private drug reimbursement programs in the context of continuing problems with the accessibility of new drugs.
"Unfortunately, only a few pharmaceutical companies are following this path as there are inherent economic obstacles," said Dr. Goodman. "There is no guarantee that the additional research and development costs associated with new drug use will return because generics do not protect their intellectual property." Pharmascience is prepared to take this risk for the benefit of society. But they need the help of authorities and drug program managers for approval and reimbursement, which will not slow down new use but will reimburse innovation. "
PHARMASCIENCE INC. INFORMATION
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical manufacturing company in Qebec with 1,500 employees based in Montreal. Pharmascience Inc. is a privately owned pharmaceutical company offering the full range of services and is rooted in Canada. With sales in over 60 countries, the global presence is growing. Capitalizing on more than $ 43 million in 2018, Pharmascience Inc. ranks 56th out of Canada's top 100 R&D investors and is the fourth largest generic drug manufacturer in the country.
Pharmascience Inc. has strong values based on the importance of investing in people and young people. The company provides personal development and life through a variety of programs and initiatives. In 2019 Pharmascience Inc. was recognized for its investment by being selected as one of Canada's Best Young Employers by the Canadian Top 100 Employers Project and named one of Montreal's best employers. In 2018, the prestigious magazine Forbes Pharmascience Inc. was among the top 300 employers.
Contact with the press:
Andrea Frascione, Communications Manager, Tel .: 514-796-4067
Original content from: Pharmascience Inc., broadcast by aktuell News